GPFT:OTC-Grapefruit USA Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.0012

Change

0.00 (0.00)%

Market Cap

USD 1.00M

Volume

5.00K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-16 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKGAF MERCK Kommanditgesellschaft au..

-15.10 (-8.46%)

USD 79.35B
MKKGY Merck KGaA ADR

+0.47 (+1.41%)

USD 78.81B
TKPHF Takeda Pharmaceutical Co. Ltd.

N/A

USD 40.01B
HLNCF Haleon plc

-0.03 (-0.71%)

USD 38.24B
TEVJF Teva Pharmaceutical Industries..

-3.30 (-18.33%)

USD 19.53B
HNSPF Hansoh Pharmaceutical Group Co..

N/A

USD 13.33B
SGIOF Shionogi & Co. Ltd

N/A

USD 12.44B
IPSEY Ipsen SA ADR

-0.21 (-0.68%)

USD 11.45B
ESAIY Eisai Co. Ltd.

+0.23 (+2.27%)

USD 11.44B
ESALF Eisai Co. Ltd

-0.88 (-2.20%)

USD 11.40B

ETFs Containing GPFT

HAL:CA Global X Active Canadian .. 3.12 % 0.78 %

-0.02 (-0.10%)

CAD 0.12B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.69% 49% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.69% 49% F 39% F
Trailing 12 Months  
Capital Gain -73.91% 21% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.91% 21% F 12% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -27.38% 29% F 9% A-
Dividend Return -27.38% 29% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 75.30% 49% F 39% F
Risk Adjusted Return -36.37% 36% F 19% F
Market Capitalization 1.00M 37% F 19% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector